PMAIP1 and cancer: Antitumor drugs targeting NOXA are widely applied in various cancers, including BH3-mimetics [49–51] and NOXA-like mimetics [52, 53], which provide an excellent precedent for the future development of NOXA-targeted therapies for IVDD.